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Abstract
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in
the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel
movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3
companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS
(diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid
(u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a
12-week double-blind treatment period followed by a 36-week open-label extension (OLE).
The primary safety and efficacy endpoints were incidence of treatment-emergent adverse
events (TEAEs) and percent change from baseline in 24-h u5-HIAA at week 12. Patients
(N = 76) were randomly assigned (1:1:1) to receive placebo or telotristat ethyl 250 mg or
500 mg 3 times per day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the
OLE. Through week 12, TEAEs were generally mild to moderate in severity; 5 (placebo),
1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg) patients experienced serious
events, and the rate of TEAEs in the OLE was comparable. At week 12, significant reductions
in u5-HIAA from baseline were observed, with Hodges–Lehmann estimators of median
treatment differences from placebo of −54.0% (95% confidence limits, −85.0%, −25.1%,
P < 0.001) and −89.7% (95% confidence limits, −113.1%, −63.9%, P < 0.001) for telotristat
ethyl 250 mg and 500 mg. These results support the safety and efficacy of telotristat ethyl
when added to SSAs in patients with CS diarrhea (ClinicalTrials.gov identifier: NCT02063659).
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Introduction
Carcinoid syndrome (CS) is a disorder that develops in up
to 20% of patients with neuroendocrine tumors (NETs) and
is characterized by severe diarrhea, flushing, abdominal
pain, and eventually cardiac valvular complications,
which can lead to heart failure (Fox & Khattar 2004,
Mamikunian et al. 2009, National Cancer Institute
2015, Davar et al. 2017, Halperin et al. 2017, National
Comprehensive Cancer Network 2017). Overproduction
of serotonin by NETs results in elevated systemic levels of
serotonin and can be measured by tracking the urinary
metabolite 5-hydroxyindoleacetic acid (u5-HIAA).
Elevated levels of serotonin occur mainly in metastatic
disease and are associated with diarrhea, one of the
most common symptoms of CS, and the development of
carcinoid heart disease; further, high levels of u5-HIAA
in patients with NETs have been associated with poor
survival (Moertel 1987, van der Horst-Schrivers et al. 2007,
Boudreaux et al. 2010, National Cancer Institute 2015,
National Comprehensive Cancer Network 2017).
Somatostatin analogs (SSAs), introduced in the mid1980s for the management of CS, are considered the
standard of care for patients suffering from this condition
(Boudreaux et al. 2010, Oberg & Lamberts 2016, National
Comprehensive Cancer Network 2017, Pavel et al. 2017b).
SSAs inhibit serotonin secretion and are an effective
initial treatment for CS, but symptoms often reoccur
over the course of the disease (Boudreaux et al. 2010,
Modlin et al. 2010).
Telotristat ethyl, previously referred to as the
hippurate salt, telotristat etiprate, is an inhibitor of
tryptophan hydroxylase, the rate-limiting enzyme in
serotonin biosynthesis (Liu et al. 2008, Kulke et al. 2017).
The phase 3 TELESTAR study demonstrated that treatment
with telotristat ethyl was generally well tolerated and was
associated with significant reductions in bowel movement
(BM) frequency and u5-HIAA levels in patients with CS
not adequately controlled by SSA therapy (≥4 BMs per day
(BMs/day) while receiving SSAs). Of note, in studies with
octreotide or lanreotide conducted prior to TELESTAR,
control of u5-HIAA levels had been a challenge, and
dose response had not been well characterized for
u5-HIAA reduction (Kvols et al. 1986, Rubin et al. 1999,
Ruszniewski et al. 2004). Telotristat ethyl at a dosage of
250 mg 3 times per day was recently approved by the
US Food and Drug Administration and the European
Commission and is a category 2A recommendation in the
National Comprehensive Cancer Network clinical practice
guidelines for the treatment of CS diarrhea inadequately
http://erc.endocrinology-journals.org
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controlled by SSA therapy (European Commission 2017,
FDA News Release 2017, Lexicon Pharmaceuticals 2017,
National Comprehensive Cancer Network 2017).
In this international, multicenter, randomized,
double-blind, placebo-controlled phase 3 companion
study, TELECAST, the safety and efficacy of telotristat
ethyl were assessed in patients with symptomatic CS
who either had <4 BMs/day with concomitant SSA
therapy (meaning that increased BM frequency was not
a primary CS symptom for these patients) or who were
not receiving concomitant SSA therapy (ClinicalTrials.
gov identifier: NCT02063659). The present TELECAST
study aims to complement the earlier TELESTAR study by
providing information on the effects of telotristat ethyl
in patients who did not qualify for TELESTAR, including
patients who were experiencing <4 BMs/day but had
other manifestations of CS such as elevated u5-HIAA or
flushing. This report constitutes the first publication of the
TELECAST results, which have previously been presented
in part (Pavel et al. 2016, 2017a).

Materials and methods
Patients
Eligible patients were ≥18 years of age and had
histopathologically
confirmed,
well-differentiated
metastatic NETs with a documented history of CS.
Patients receiving SSA therapy for the treatment of CS
prior to the study were required to be on stable-dose
SSAs (long-acting release, depot or infusion pump) for
at least 3 months prior to enrollment, be experiencing
an average of <4 BMs/day and have at least 1 of the
following signs or symptoms: (1) daily stool consistency
≥5 on the Bristol Stool Form scale (1 (hard lumps) to
7 (watery liquid)) for ≥50% of the days during the
run-in period (indicating that the patient had diarrhea
or stools that were softer than normal) (Longstreth et al.
2006); (2) average daily cutaneous flushing frequency
of ≥2; (3) average daily rating of ≥3 for abdominal
pain; (4) nausea present ≥20% of days or (5) u5-HIAA
above the upper limit of normal (ULN). For patients not
receiving SSA therapy, eligibility depended on having at
least 1 of the above signs or symptoms or an average of
≥4 BMs/day.
Patients were excluded if they met any of the
following criteria: had diarrhea attributable to any
condition other than CS; were experiencing ≥4 BMs/day
This work is licensed under a Creative Commons
Attribution 4.0 International License.
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while on concomitant SSA therapy; showed evidence
of enteric infection; had a Karnofsky performance
status ≤60%; had a history of short bowel syndrome or
chronic or idiopathic constipation; showed clinically
important baseline elevation in liver function tests or
had undergone tumor-directed therapy within 4 weeks
prior to screening or hepatic embolization, radiotherapy,
radiolabeled SSA therapy and/or tumor debulking within
12 weeks prior to screening. Additional exclusion criteria
are described in the Supplementary methods (see section
on supplementary data given at the end of this article).
Study design and treatment
Patient baseline symptoms were established by a
screening/run-in period of at least 3 weeks. Randomization
was stratified by baseline u5-HIAA levels (categories
of ≤ULN, >ULN, and unknown (missing at the time
of randomization or uninterpretable)). Patients were
randomly assigned 1:1:1 to receive oral doses of telotristat
ethyl 250 mg or 500 mg 3 times per day (tid) or placebo
tid during the double-blind treatment (DBT) period of
12 weeks. Patients assigned to the telotristat ethyl 500 mg
group underwent a blinded titration, receiving telotristat
ethyl 250 mg tid for the first 7 days. Following the DBT
period, patients could opt to continue treatment with
telotristat ethyl 500 mg tid in a 36-week open-label
extension (OLE) period. For patients treated with placebo
during the DBT period, a blinded titration with telotristat
ethyl 250 mg occurred during the initial 7-day OLE period,
followed by an increase to telotristat ethyl 500 mg after
7 days. Downward dose adjustment was allowed during
the OLE in cases of intolerability. Rescue short-acting SSA
use was allowed and unrestricted during the study, and
patients continued to receive their baseline stable-dose
SSA therapy.
The study protocol and amendments were approved by
the institutional review board or ethics committee at each
center, and the study was conducted in agreement with
Good Clinical Practice guidelines and the Declaration of
Helsinki. All patients provided written informed consent.
Efficacy and safety assessments
The primary safety and efficacy endpoints were the
incidence of treatment-emergent adverse events (TEAEs)
and percent change from baseline in 24-h u5-HIAA
levels at week 12, respectively. Adverse events (AEs) were
graded in severity by the investigator as mild, moderate
or severe. Event severity grading is fully described in the
http://erc.endocrinology-journals.org
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Supplementary methods. Depression-related AEs were
prespecified as AEs of special interest (AESIs). Although
not defined as such in the protocol, gastrointestinal
disorder AEs and hepatic-enzyme-related AEs were also
considered AESIs based on clinical experience in phase 1
and 2 studies. Planned efficacy analyses were based on the
intent-to-treat population.
Key secondary efficacy endpoints included the change
from baseline averaged over the 12-week DBT period for
daily BM frequency, stool consistency, cutaneous flushing
episodes, abdominal pain and frequency of rescue shortacting SSA treatment. Additional analyses of efficacy
endpoints included durability of response to treatment
(a durable response was predefined in the statistical analysis
plan as a ≥30% reduction in BM frequency for ≥50% of
each patient’s days on treatment in the DBT period).
Patient-reported measures were collected via an
electronic patient diary (eDiary), which was identical to
the one used in the TELESTAR study (Kulke et al. 2017) and
was completed for BMs/day, number of cutaneous flushing
episodes, abdominal pain/discomfort, sensation/severity
of nausea, stool form/consistency, urgency to defecate,
subjective global assessment of symptoms associated with
CS, adequate relief of gastrointestinal symptoms of CS
and need for self-administered rescue short-acting SSA
therapy to treat symptoms associated with CS.
Statistical analysis
Statistical analyses were performed using SAS statistical
software (SAS Institute, Cary, NC, USA), version 9.3
or higher for the efficacy endpoints. Statistical testing
used a two-sided α-level set at 0.05 in determining the
significance. A blocked 2-sample Wilcoxon rank-sum
statistic (stratified by baseline u5-HIAA levels) was used
to evaluate treatment group differences for the primary
efficacy endpoint. The nonparametric Hodges–Lehmann
estimator of the median paired treatment difference was
used to describe the magnitude of treatment effect. Sample
size was based on percent change from baseline in 24-h
u5-HIAA levels at week 12. Sixteen patients per arm would
enable a power of 80% to detect a difference in u5-HIAA
levels, assuming the difference between the treatment
groups was 40% and the common standard deviation was
35%, leading to an effect size (mean/standard deviation)
of 1.143. A target reduction of 40% was chosen to reduce
the risk of capturing changes due to natural variability of
u5-HIAA levels; this is higher than the threshold in prior
studies with NETs in which secretory biomarker reduction
of ≥30% has been used as a measure of treatment efficacy
This work is licensed under a Creative Commons
Attribution 4.0 International License.
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(Kulke et al. 2017, Yao et al. 2011). The evaluation of the
safety endpoint was qualitative, and no statistical analyses
were performed. Full statistical methods are described in
the Supplementary methods.

Results
Patient characteristics
From April 2014 to April 2015, 76 patients from 11
countries were randomly assigned (1:1:1) to receive
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telotristat ethyl 250 mg tid, telotristat ethyl 500 mg tid
or placebo tid (Fig. 1). The patient demographics and
baseline characteristics are described in Table 1. They
were well balanced across many of the characteristics (age,
sex, ethnicity, race, weight, height, baseline body mass
index, baseline u5-HIAA level); however, there were some
exceptions with respect to differences in concomitant
therapies. At baseline, mean BMs/day ranged from 2.2 to
2.8, whereas mean u5-HIAA levels ranged from 66.0 mg to
86.3 mg per 24 h. Across all study arms, at least 68.4% of
patients had u5-HIAA levels greater than the ULN. Patients

Assessed for eligibility
(N=94)

Enrollment

25:3

Randomly allocated 1:1:1
(n=76; n random allocations)

Excluded (n=18)
Not meeting inclusion/met exclusion criteria (n=11)
Declined to participate or withdrew consent (n=1)
Physician decision (n=1)
Compliance failure (n=3)
Death (n=0)
Unknown reasons (n=2)

Allocation (DBT)
Allocated to placebo (n=26)
Received allocated intervention (n=26)
Did not receive allocated intervention (n=0)

Allocated to telotristat ethyl 250 mg tid (n=25)
Received allocated intervention (n=25)
Did not receive allocated intervention (n=0)

Allocated to telotristat ethyl 500 mg tid (n=25)
Received allocated intervention (n=25)
Did not receive allocated intervention (n=0)

Follow-up
Completed the DBT period (n=24)
Discontinued intervention in DBT period (n=2)
Lost to follow-up (n=0)
Adverse event (n=1)
Physician decision (n=1)
Withdrawal of consent (n=0)

Completed the DBT period (n=22)
Discontinued intervention in DBT period (n=3)
Lost to follow-up (n=0)
Adverse event (n=2)
Physician decision (n=0)
Withdrawal of consent (n=1)

Completed the DBT period (n=22)
Discontinued intervention in DBT period (n=3)
Lost to follow-up (n=0)
Adverse event (n=0)
Physician decision (n=0)
Withdrawal of consent (n=3)

Analysis
Analyzed (n=22)
Excluded from analysis (n=2)
u5-HIAA sample not collected or
analyzed, or collected late (n=2)

Analyzed (n=17)
Excluded from analysis (n=5)
u5-HIAA sample not collected or
analyzed, or collected late (n=5)

Analyzed (n=19)
Excluded from analysis (n=3)
u5-HIAA sample not collected or
analyzed, or collected late (n=3)

Allocation (OLE)
Entered the OLE period (n=24)

Entered the OLE period (n=22)

Entered the OLE period (n=21)

All patients treated with
telotristat ethyl 500 mg tid
Completed the OLE period (n=15)
Discontinued intervention in the OLE period (n=9)
Lost to follow-up (n=0)
Adverse event (n=4)
Death (n=0)
Lack of efficacy (n=0)
Physician decision (n=0)
Withdrawal of consent (n=4)
Other (n=1)

Completed the OLE period (n=19)
Discontinued intervention in the OLE period (n=3)
Lost to follow-up (n=0)
Adverse event (n=2)
Death (n=0)
Lack of efficacy (n=0)
Physician decision (n=0)
Withdrawal of consent (n=1)
Other (n=0)

Completed the OLE period (n=13)
Discontinued intervention in the OLE period (n=8)
Lost to follow-up (n=0)
Adverse event (n=1)
Death (n=0)
Lack of efficacy (n=1)
Physician decision (n=1)
Withdrawal of consent (n=4)
Other (n=1)

Figure 1
CONSORT diagram of the TELECAST clinical trial. Patient flow in the TELECAST study. DBT, double-blind treatment; OLE, open-label extension; tid,
3 times per day.
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Table 1 Demographic and baseline characteristics of the patient population.
DBT

OLE

Patient characteristics

Placebo (n = 26)

Telotristat ethyl
250 mg tid (n = 25)

Telotristat ethyl
500 mg tid (n = 25)

Telotristat ethyl
500 mg tid (n = 67)

Mean age, years (s.d.)
Median age (range)
Male, n (%)
u5-HIAA at randomization, n (%)a
≤ULN
>ULN
Unknown
Mean u5-HIAA at baseline, mg/day (median)
Mean BM frequency, counts/day (s.d.)b
Averaging ≥1 BM/day at baseline, n (%)
Averaging ≥4 BMs/dayc at baseline, n (%)
Mean weekly stool consistency score (s.d.)b
Mean number of flushing episodes/day (s.d.)b
Mean weekly abdominal pain rating (s.d.)b
SSA therapy at study entry, n (%)
Octreotide
Lanreotide
Unknown
Not on SSA

62.2 (10.3)
65.0 (41–78)
13 (50.0)

63.6 (12.6)
62.0 (38–84)
14 (56.0)

62.7 (12.0)
63.0 (35–83)
15 (60.0)

63.3 (11.4)
64.0 (35–84)
39 (58.2)

9 (34.6)
17 (65.4)
0
82.0 (31.1)
2.2 (0.7)
25 (96.2)
0
5.0 (0.9)
3.7 (4.1)
1.7 (1.7)

5 (20.0)
18 (72.0)
2 (8.0)
86.3 (84.0)
2.5 (1.2)
24 (96.0)
1 (4.0)
5.1 (0.8)
2.7 (3.7)
1.2 (1.5)

8 (32.0)
17 (68.0)
0
66.0 (40.0)
2.8 (1.6)
24 (96.0)
4 (16.0)
5.3 (0.8)
1.8 (2.2)
1.8 (1.7)

19 (28.4)
46 (68.7)
2 (3.0)
78.2 (43.1)
2.4 (1.1)
64 (95.5)
3 (4.5)
5.1 (0.9)
2.6 (3.1)
1.5 (1.7)

12 (46.2)
14 (53.8)
0
0

17 (68.0)
5 (20)
0
3 (12.0)

16 (64.0)
3 (12.0)
1 (4.0)
5 (20.0)

40 (59.7)
20 (29.9)
1 (1.5)
6 (9.0)

range: normal u5-HIAA ≤0–15 mg per 24 h (Tellez et al. 2013); bbaseline diary endpoints for placebo (n = 25) and OLE (n = 66); cthese patients
were not currently receiving LAR/depot/infusion SSA therapy.
BM, bowel movement; DBT, double-blind treatment; OLE, open-label extension; s.d., standard deviation; SSA, somatostatin analog; tid, 3 times per day;
u5-HIAA, urinary 5-hydroxyindoleacetic acid; ULN, upper limit of normal.
aReference

were diagnosed with a NET an average of 7.8 years prior to
inclusion in this study (standard deviation (s.d.) 3.8 years;
median 9.1 years; range 0.6–19.1 years). Approximately
90% (n = 68) of patients had medical histories of
gastrointestinal disorders, most commonly diarrhea; 58%
(n = 44) had metabolic and nutrition disorders, which
included vitamin deficiencies, electrolyte abnormalities
and malnutrition; and 42% (n = 32) of patients had a
history of cardiac disorders, which included carcinoid
heart disease in 9, 6 and 5 patients on placebo, telotristat
ethyl 250 mg and telotristat ethyl 500 mg, respectively.

Of the 68 patients who completed the DBT period, 67
were enrolled in the OLE period. Patients who entered the
OLE period received a mean of 30.3 additional weeks of
telotristat ethyl exposure (median 36.0 weeks) from week
13 to week 48. More than half of patients who started the
OLE period (47/67, 70.1%) completed the full OLE period,
and compliance was 76.1%. The most common reasons
for discontinuation in both the DBT and OLE periods
were withdrawal of consent (n = 4 for DBT and n = 9 for
OLE) and AEs (n = 3 for DBT and n = 7 for OLE).
Primary endpoint: safety

Patient disposition
In this study, 26 patients received placebo, 25 patients
received telotristat ethyl 250 mg tid and 25 patients
received telotristat ethyl 500 mg tid in the DBT period
(Fig. 1). A total of 68 patients completed the DBT period:
22 patients per telotristat ethyl group (88.0%) and 24
patients (92.3%) in the placebo group. The mean telotristat
ethyl exposure time during the DBT period was 11.5 weeks
(median 12.0 weeks). Mean compliance was 91.8% (s.d.
12.1%) and 92.8% (s.d. 11.8%) for the telotristat ethyl
250 mg and telotristat ethyl 500 mg groups, respectively,
and 96.7% (s.d. 4.8%) for the placebo group. Reasons for
withdrawal or discontinuation are shown in Fig. 1.
http://erc.endocrinology-journals.org
https://doi.org/10.1530/ERC-17-0455

© 2018 The authors
Published by Bioscientifica Ltd.
Printed in Great Britain

During the DBT period, the overall incidence of any
TEAEs was similar among all groups (Table 2). During
the DBT period, 5 patients (19.2%) in the placebo group
experienced a serious adverse event (SAE), whereas only
1 patient (4.0%) and 3 patients (12.0%) experienced a
SAE in the telotristat ethyl 250 mg and telotristat ethyl
500 mg groups, respectively. TEAEs that were considered
‘treatment related’ by investigators occurred more
frequently in the telotristat ethyl treatment groups
compared with the placebo group. Across all 3 groups,
there were no deaths during the DBT or OLE periods. Only
3 patients discontinued the study drug during the DBT
period because of a TEAE: 1 patient in the placebo group
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Table 2 Number of patients with TEAEs reported in the DBT and OLE periods.
DBT
Category, n (%)

Any TEAE
TEAE by severitya
Mild
Moderate
Severe
Treatment-related TEAEs
Serious TEAEsb
Treatment-related serious TEAEsc
Study discontinuation due to TEAEsd
TEAE resulting in death

OLE

Placebo (n = 26)

Telotristat ethyl
250 mg tid (n = 25)

Telotristat ethyl
500 mg tid (n = 25)

Telotristat ethyl
500 mg tid (n = 67)

21 (80.8)

25 (100.0)

22 (88.0)

61 (91.0)

9 (34.6)
11 (42.3)
1 (3.8)
7 (26.9)
5 (19.2)
0
1 (3.8)
0

9 (36.0)
13 (52.0)
3 (12.0)
10 (40.0)
1 (4.0)
0
2 (8.0)
0

10 (40.0)
11 (44.0)
1 (4.0)
11 (44.0)
3 (12.0)
0
0
0

11 (16.4)
30 (44.8)
20 (29.9)
28 (41.8)
17 (25.4)
2 (3.0)
7 (10.4)
0

grades are defined in the Supplementary methods; patients with ≥1 TEAE in a given period are counted once at the maximum severity across
all the patient’s TEAEs for that period; blife-threatening AE, death, hospitalization, persistent or significant incapacity or disruption of ability to conduct
normal life functions, or congenital anomaly or birth defect; ctreatment-related serious TEAEs during the OLE period were acute myocardial infarction
and small intestinal hemorrhage (1 patient each); dTEAEs leading to study discontinuation in the DBT period were upper abdominal pain, diarrhea,
and tumor progression (1 patient each), and in the OLE period they were small intestinal hemorrhage, performance status decrease, elevated
gamma-glutamyl transferase or hepatic enzymes, tumor progression (1 patient each), and depression (2 patients).
AE, adverse event; DBT, double-blind treatment; OLE, open-label extension; TEAE, treatment-emergent adverse event; tid, 3 times per day.
aSeverity

(malignant neoplasm progression) and 2 patients in the
telotristat ethyl 250 mg group (upper abdominal pain and
diarrhea). Most TEAEs were rated as mild or moderate
in severity and were most commonly gastrointestinal in
nature (Tables 2 and 3).
During the OLE, the types of safety-related events,
incidences of overall TEAEs and incidences of TEAEs
leading to study discontinuation were similar to those
in the DBT period, considering the increased exposure to
telotristat ethyl. Crossover from placebo or telotristat ethyl
250 mg to telotristat ethyl 500 mg in the OLE period did
not affect the incidence of TEAEs. During the OLE period,
only 2 patients required downward dose adjustment to
250 mg telotristat ethyl tid. TEAEs were generally mild or
moderate in intensity, with the most frequently reported
incidence being gastrointestinal in nature, specifically
nausea. Four patients had TEAEs that were reported as both
severe and treatment related by the investigator (Table 2;
1 patient each: acute myocardial infarction, constipation,
a small intestinal hemorrhage and an increase in gammaglutamyl transferase (GGT)).
AEs of special interest included depression,
gastrointestinal disorders and hepatic enzyme elevations
(Table 4) based on mechanism of action or previous clinical
experience with telotristat ethyl (Liu et al. 2008, Kulke
et al. 2017). There was no increase in depression-related
AEs on telotristat ethyl compared with placebo, and no
severe or serious cases in either the DBT or OLE period.
Two patients suffered from AEs related to depression (both
of moderate severity), leading to study discontinuation in
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the OLE period; both patients had underlying depression
and were receiving antidepressant therapy at baseline.
AEs of special interest related to hepatic enzyme
abnormalities were mostly mild or moderate in severity.
Two events led to study discontinuation during the
OLE period. One patient experienced elevated alanine
aminotransferase (ALT), alkaline phosphatase (ALP),
aspartate aminotransferase (AST) and GGT. Telotristat
ethyl was discontinued, and the patient’s hepatic enzymes
normalized within 3 months. Another patient had an
underlying condition of elevated GGT levels at baseline
and throughout the course of the study. A follow-up
visit during the OLE period found that GGT levels had
increased approximately 6-fold above baseline, and
telotristat ethyl was discontinued. During the DBT period,
2 patients (1 in each telotristat ethyl group) experienced
an increase in GGT, 1 patient in the telotristat ethyl 250 mg
group experienced an increase in ALT and 1 patient in the
telotristat ethyl 500 mg group experienced an abnormal
liver function test; however, there were no associated
increases in bilirubin.
Gastrointestinal
disorders
(diarrhea,
nausea,
constipation, abdominal pain, abdominal distension,
dyspepsia, vomiting and abdominal discomfort) were
frequent TEAEs for all groups in both the DBT and OLE
periods; however, there was no dose-dependent or drugdependent relationship between telotristat ethyl and
gastrointestinal symptoms. The most frequent severe
TEAE observed in the DBT period (3 patients), abdominal
pain, was seen in only 1 patient during the OLE period.
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Attribution 4.0 International License.
Downloaded from Bioscientifica.com at 02/11/2019 03:25:07PM
via University of Kentucky

Endocrine-Related
Cancer

M Pavel et al.

315

25:3

Telotristat ethyl for carcinoid
syndrome

Table 3 Incidence of TEAEs in ≥5% of patients in any group.
DBT
System organ class preferred term, n (%)

disorders†

Placebo (n = 26)

Blood and lymphatic system
Anemia
Cardiac disorders†
Ear and labyrinth disorders†
Gastrointestinal disorders†
Nausea
Abdominal pain
Diarrhea
Constipation
Vomiting
Abdominal pain upper
Abdominal distension
Dyspepsia
General disorders and administration site conditions†
Fatigue
Pyrexia
Asthenia
Peripheral edema
Infections and infestations†
Urinary tract infection
Influenza
Nasopharyngitis
Injury, poisoning, and procedural complications†,a
Investigations†,b
Gamma-glutamyl transferase increase
Weight decreased
Metabolism and nutrition disorders†
Decreased appetite
Musculoskeletal and connective tissue disorders†,b
Myalgia
Musculoskeletal pain
Arthralgia
Back pain
Neoplasms benign, malignant, and unspecified
(including cysts and polyps)†
Nervous system disorders†
Dizziness
Headache
Presyncope
Psychiatric disorders†,b
Depression
Depressed mood
Renal and urinary disorders†
Respiratory, thoracic, and mediastinal disorders†
Dyspnea
Oropharyngeal pain
Cough
Skin and subcutaneous tissue disorders†
Night sweats
Surgical and medical procedures†
Vascular disorders†
Flushing

Telotristat ethyl
250 mg tid (n = 25)

OLE
Telotristat ethyl
500 mg tid (n = 25)

Telotristat ethyl
500 mg tid (n = 67)

1 (3.8)
0
2 (7.7)
0
15 (57.7)
4 (15.4)
4 (15.4)
5 (19.2)
1 (3.8)
1 (3.8)
3 (11.5)
0
2 (7.7)
6 (23.1)
2 (7.7)
0
2 (7.7)
0
5 (19.2)
0
0
1 (3.8)
1 (3.8)
3 (11.5)
0
0
0
0
4 (15.4)
2 (7.7)
0
1 (3.8)
1 (3.8)
1 (3.8)

1 (4.0)
1 (4.0)
0
0
16 (64.0)
3 (12.0)
8 (32.0)
4 (16.0)
4 (16.0)
1 (4.0)
1 (4.0)
3 (12.0)
2 (8.0)
8 (32.0)
3 (12.0)
3 (12.0)
1 (4.0)
2 (8.0)
8 (32.0)
3 (12.0)
0
1 (4.0)
0
3 (12.0)
1 (4.0)
1 (4.0)
1 (4.0)
0
1 (4.0)
1 (4.0)
0
0
0
1 (4.0)

1 (4.0)
1 (4.0)
0
0
10 (40.0)
2 (8.0)
1 (4.0)
2 (8.0)
3 (12.0)
1 (4.0)
2 (8.0)
1 (4.0)
0
4 (16.0)
2 (8.0)
0
0
1 (4.0)
5 (20.0)
0
2 (8.0)
0
1 (4.0)
2 (8.0)
1 (4.0)
0
2 (8.0)
2 (8.0)
5 (20.0)
1 (4.0)
2 (8.0)
0
0
4 (16.0)

4 (6.0)
4 (6.0)
12 (17.9)
4 (6.0)
39 (58.2)
14 (20.9)
12 (17.9)
9 (13.4)
8 (11.9)
7 (10.4)
5 (7.5)
4 (6.0)
0
24 (35.8)
7 (10.4)
6 (9.0)
7 (10.4)
5 (7.5)
17 (25.4)
3 (4.5)
1 (1.5)
5 (7.5)
9 (13.4)
18 (26.9)
4 (6.0)
4 (6.0)
14 (20.9)
6 (9.0)
22 (32.8)
2 (3.0)
2 (3.0)
4 (6.0)
5 (7.5)
5 (7.5)

5 (19.2)
3 (11.5)
1 (3.8)
0
2 (7.7)
0
2 (7.7)
1 (3.8)
3 (11.5)
2 (7.7)
0
0
1 (3.8)
0
1 (3.8)
4 (15.4)
2 (7.7)

2 (8.0)
0
0
1 (4.0)
2 (8.0)
0
1 (4.0)
3 (12.0)
3 (12.0)
1 (4.0)
2 (8.0)
1 (4.0)
6 (24.0)
2 (8.0)
0
5 (20.0)
3 (12.0)

3 (12.0)
2 (8.0)
1 (4.0)
0
2 (8.0)
1 (4.0)
0
0
1 (4.0)
0
0
0
3 (12.0)
1 (4.0)
0
2 (8.0)
0

16 (23.9)
3 (4.5)
5 (7.5)
5 (7.5)
16 (23.9)
8 (11.9)
2 (3.0)
8 (11.9)
13 (19.4)
4 (6.0)
1 (1.5)
4 (6.0)
10 (14.9)
1 (1.5)
8 (11.9)
15 (22.4)
9 (13.4)

†Subcategories

experienced by <5% of patients are not included; apreferred terms included for injury, poisoning, and procedural complications are listed
in the Supplementary methods. Each of these categories was experienced by <5% of patients; bpreferred terms also included for investigations,
musculoskeletal and connective tissue disorders, and psychiatric disorders are listed in the Supplementary methods. Each of these categories was
experienced by <5% of patients.
DBT, double-blind treatment; OLE, open-label extension; TEAE, treatment-emergent adverse event; tid, 3 times per day.
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Table 4 Adverse events of special interest.
DBT
AESI category preferred term, n (%)

Gastrointestinal-related TEAE
Abdominal pain

Diarrhea

Nausea

Constipation

Abdominal pain upper

Abdominal distension

Abdominal discomfort

Flatulence

Abdominal tenderness

Frequent bowel movements

Abdominal pain lower

Gastrointestinal pain

Vomiting

Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe

Placebo tid (n = 26)

Telotristat ethyl
250 mg tid (n = 25)

4 (15.4)
1 (3.8)
3 (11.5)
0
5 (19.2)
2 (7.7)
3 (11.5)
0
4 (15.4)
4 (15.4)
0
0
1 (3.8)
0
1 (3.8)
0
3 (11.5)
2 (7.7)
1 (3.8)
0
0
0
0
0
1 (3.8)
1 (3.8)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1 (3.8)
0
1 (3.8)
0

8 (32.0)
3 (12.0)
3 (12.0)
2 (8.0)
4 (16.0)
2 (8.0)
2 (8.0)
0
3 (12.0)
2 (8.0)
1 (4.0)
0
4 (16.0)
3 (12.0)
1 (4.0)
0
1 (4.0)
0
1 (4.0)
0
3 (12.0)
2 (8.0)
1 (4.0)
0
0
0
0
0
1 (4.0)
1 (4.0)
0
0
0
0
0
0
1 (4.0)
0
1 (4.0)
0
0
0
0
0
0
0
0
0
1 (4.0)
1 (4.0)
0
0

OLE
Telotristat ethyl
500 mg tid (n = 25)

1 (4.0)
0
0
1 (4.0)
2 (8.0)
1 (4.0)
1 (4.0)
0
2 (8.0)
2 (8.0)
0
0
3 (12.0)
3 (12.0)
0
0
2 (8.0)
2 (8.0)
0
0
1 (4.0)
1 (4.0)
0
0
1 (4.0)
1 (4.0)
0
0
1 (4.0)
1 (4.0)
0
0
1 (4.0)
1 (4.0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1 (4.0)
0
1 (4.0)
0

Telotristat ethyl
500 mg tid (n = 67)

12 (17.9)
5 (7.5)
6 (9.0)
1 (1.5)
9 (13.4)
3 (4.5)
4 (6.0)
2 (3.0)
14 (20.9)
8 (11.9)
5 (7.5)
1 (1.5)
8 (11.9)
5 (7.5)
2 (3.0)
1 (1.5)
5 (7.5)
3 (4.5)
2 (3.0)
0
4 (6.0)
4 (6.0)
0
0
1 (1.5)
1 (1.5)
0
0
2 (3.0)
1 (1.5)
1 (1.5)
0
0
0
0
0
0
0
0
0
1 (1.5)
0
1 (1.5)
0
1 (1.5)
1 (1.5)
0
0
7 (10.4)
4 (6.0)
2 (3.0)
1 (1.5)
(Continued)
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Table 4 Continued.
DBT
AESI category preferred term, n (%)

Depression-related TEAE
Depressed mood

Decreased interest

Depression

Hepatic-enzyme-related TEAE
Elevated gamma-glutamyl
transferase

Elevated alanine
aminotransferase

Liver function test abnormal

Elevated aspartate
aminotransferase

Blood alkaline phosphatase
increased

Hepatic enzyme increased

Placebo tid (n = 26)

Telotristat ethyl
250 mg tid (n = 25)

OLE
Telotristat ethyl
500 mg tid (n = 25)

Telotristat ethyl
500 mg tid (n = 67)

Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe

2 (7.7)
2 (7.7)
0
0
1 (3.8)
1 (3.8)
0
0
0
0
0
0

1 (4.0)
1 (4.0)
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
1 (4.0)
0
1 (4.0)
0

2 (3.0)
2 (3.0)
0
0
0
0
0
0
8 (11.9)
4 (6.0)
4 (6.0)
0

Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe
Total
Mild
Moderate
Severe

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1 (4.0)
1 (4.0)
0
0
1 (4.0)
1 (4.0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

1 (4.0)
0
1 (4.0)
0
0
0
0
0
1 (4.0)
1 (4.0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0

4 (6.0)
1 (1.5)
1 (1.5)
2 (3.0)
3 (4.5)
2 (3.0)
0
1 (1.5)
1 (1.5)
0
1 (1.5)
0
3 (4.5)
2 (3.0)
0
1 (1.5)
2 (3.0)
1 (1.5)
1 (1.5)
0
2 (3.0)
1 (1.5)
1 (1.5)
0

AESI, adverse event of special interest; DBT, double-blind treatment; OLE, open-label extension; TEAE, treatment-emergent adverse event; tid, 3 times
per day.

Constipation was reported more often on telotristat ethyl
than placebo. Constipation was rated as mild to moderate
in 7 of the 8 patients reporting this event during the OLE
period. Nausea occurred with similar frequencies among
patients treated with placebo and telotristat ethyl during
the DBT period and did not result in SAEs or treatment
discontinuation.
There were no significant changes in vital signs
(other than weight), electrocardiogram measurements
or physical examination findings during the DBT period.
With respect to weight, 2 (8.7%), 4 (17.4%) and 5 (20.8%)
patients in the placebo, telotristat ethyl 250 mg and the
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telotristat ethyl 500 mg groups, respectively, had at least
a 3% gain in body weight during the DBT period. The 3
patients with electrocardiogram changes outside of the
normal range were on placebo, and 2 had underlying
histories of cardiac disorders. Electrocardiogram measures
included heart rate, PR duration, QRS duration and QT
interval and are summarized in Supplementary Table 1.
Primary endpoint: efficacy
A statistically significant reduction from baseline in
u5-HIAA levels was observed at week 12 for both the
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telotristat ethyl 250 mg and telotristat ethyl 500 mg
groups compared with the placebo group (P < 0.001 for
each comparison) and continued through the OLE period
for the majority of patients (Fig. 2). Baseline and week

Mean Change From Baseline (%) in
u5-HIAA Levels

A

100.0

97.7%

Placebo

80.0

Telotristat ethyl 250 mg tid

60.0

Telotristat ethyl 500 mg tid

40.0

HL treatment
difference vs
a
placebo
–54.0% –89.7%

20.0

Crossover from placebo
Crossover from telotristat ethyl 250 mg tid

0.0
–20.0

–12.8%

–40.0

–33.2%

–60.0
–80.0

–76.5%

–72.6%

Week 12
Patients (n) 22b

17

19

–62.5%

–57.5%
–69.4%

Week 18
17

18

Percentage Change From Baseline
in u5-HIAA Levels at Week 12

Percentage Change From Baseline
in u5-HIAA Levels at Week 12

C

200
180
160
140
120
100
80
60
40
20
0
–20
–40
–60
–80
–100

200
180
160
140
120
100
80
60
40
20
0
–20
–40
–60
–80
–100

20

14

Week 48
15

OLE Period

Placebo (n=22)

Placebo (n=22)

–59.5%

–71.7%

Week 24
17

DBT Period

B

–50.8%
–61.5%

15

18

10

c

Telotristat ethyl 250 mg tid (n=17)

Telotristat ethyl 500 mg tid (n=19)

Figure 2
Changes in u5-HIAA levels from baseline. (A) The Hodges–Lehmann (HL)
estimator, a nonparametric measure used to describe the magnitude of
treatment effect, was assessed at week 12 (aP < 0.001). bData include 1
patient who experienced a 1864.5% increase from baseline. cThe colors
and shapes in each bar represent the assigned treatment group during
the double-blind treatment (DBT) period; clear bars with filled shapes
indicate treatment of these patients with telotristat ethyl 500 mg 3 times
per day (tid) during the open-label extension (OLE) period. (B) The
distribution of individual patient responses to treatment with telotristat
ethyl 250 mg tid or placebo, as percent change from baseline at week 12.
One patient treated with placebo had a 1864.5% change from baseline
and is not included in the figure. (C) The distribution of individual patient
responses to treatment with telotristat ethyl 500 mg tid or placebo, as
percent change from baseline at week 12. One patient treated with
placebo had a 1864.5% change from baseline and is not included in the
figure. u5-HIAA, urinary 5-hydroxyindoleacetic acid.
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12 values were available for 17, 19 and 22 patients in
the telotristat ethyl 250 mg, telotristat ethyl 500 mg and
placebo groups, respectively. Ten patients who completed
the DBT period were excluded from the primary efficacy
analysis because of deviations related to u5-HIAA sample
collection or analysis. At week 12, significant reductions in
u5-HIAA levels from baseline were observed with Hodges–
Lehmann estimator of treatment differences from placebo
of −54.0% (95% confidence limits (CL) −85.0%, −25.1%)
for the 250 mg telotristat ethyl group and −89.7% (95%
CL −113.1%, −63.9%) for the 500 mg telotristat ethyl
group (P < 0.001 for both vs placebo). Additionally, more
patients in the telotristat ethyl groups demonstrated a
reduction in u5-HIAA levels at week 12 compared with
the placebo group (15 of 17 patients for telotristat ethyl
250 mg, 19 of 19 patients for telotristat ethyl 500 mg and
8 of 22 patients for placebo).
Additional efficacy endpoints
Treatment with telotristat ethyl at either dosage was also
associated with statistically significant reductions in BMs/
day averaged over the 12-week DBT period compared
with placebo (P = 0.004 for telotristat ethyl 250 mg and
P < 0.001 for telotristat ethyl 500 mg, Table 5; percent
change in BM frequency from baseline per week is shown
in Fig. 3). The Hodges–Lehmann estimator of treatment
difference from placebo for patients receiving telotristat
ethyl was −0.45 for the telotristat ethyl 250 mg group
and −0.54 for the telotristat ethyl 500 mg group. Durable
responses (predefined in the statistical analysis plan as
responders with ≥30% reduction in daily number of BMs
for ≥50% of the time over the DBT period) were observed
only in patients on telotristat ethyl. Ten patients in each
telotristat ethyl group (40.0%) were classified as durable
responders, whereas none of the patients who received
placebo were classified as durable responders (treatment
difference in responder rate of 0.40; 95% CL 0.17, 0.63;
P = 0.001). During the DBT period, a mean reduction in BM
frequency by approximately 1 BM/day was also observed
in the small number (n = 8) of telotristat ethyl–treated
patients who were not on concurrent SSA therapy. The
mean reduction in BMs/day observed in the DBT period
for telotristat ethyl–treated patients continued through
the OLE period.
Telotristat ethyl 500 mg had a statistically significant
(P = 0.009) effect on stool form/consistency, as measured
by the Bristol Stool Form scale, compared with placebo
during the DBT period. From the Hodges–Lehmann
estimator, there was a difference of −0.39 (95% CL −0.82,
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Table 5 Secondary endpoints of the double-blind treatment period.
Placebo
(n = 25)
Variable

Telotristat ethyl

Mean (s.d.)

BM frequency
Change from baseline in
0.05 (0.33)
BM frequency averaged
over 12 weeks, counts/day
Arithmetic mean
−
treatment difference
Hodges–Lehmann
−
estimator
Stool consistency
Change from baseline in
0.01 (0.41)
stool consistency
averaged over 12 weeks
(Bristol Stool Form scale)
Arithmetic mean
−
treatment difference
Hodges–Lehmann
−
estimator
Flushing
Change from baseline in
−0.33 (1.22)
daily cutaneous flushing
episodes averaged over
12 weeks, counts/day
Arithmetic mean
−
treatment difference
Hodges–Lehmann
−
estimator
Abdominal pain
Change from baseline in
−0.06 (0.78)
abdominal pain
averaged over 12 weeks,
11-point numeric rating
scale
Arithmetic mean
−
treatment difference
Hodges–Lehmann
−
estimator
Rescue short-acting SSA use
Change from baseline in
−0.01 (0.14)
rescue short-acting SSA
use averaged over
12 weeks, counts/day
Arithmetic mean
−
treatment difference
Hodges–Lehmann
−
estimator

250 mg tid (n = 25)
Mean (s.d.)
P

500 mg tid (n = 25)
P

95% CL

Mean (s.d.)

95% CL

−0.60 (0.72)

−

−

−0.45 (0.69)

−

−

−0.50

−

−0.81 to −0.19

−0.65

−

−0.96 to −0.33

−0.45

0.004

−0.72 to −0.17

−0.54

<0.001

−0.79 to −0.25

−0.20 (0.70)

–

−0.20

–

−0.20

0.09

−0.06 (0.98)

–

−0.60 (0.86)

–

−0.53 to 0.13

−0.60

–

−0.45 to 0.02

−0.39

–

–

0.009

0.11 (2.10)

–

–

−0.99 to −0.22
−0.82 to −0.12
–

0.27

–

−0.36 to 0.90

0.45

–

−0.53 to 1.42

0.11

0.67

−0.17 to 0.61

0.02

0.58

−0.28 to 0.62

−0.23 (0.97)

–

−0.17

–
0.61

0.06
−0.07 (0.35)

–

−0.05

–
0.45

0.00

–

0.03 (0.77)

–

−0.67 to 0.33

0.09

–

−0.35 to 0.53

−0.42 to 0.33

0.14

0.66

−0.39 to 0.51

–

0.01 (0.10)

–

−0.20 to 0.10

0.02

–

0.00–0.00

0.000

0.98

–

–

−0.05 to 0.09
0.00–0.00

BM, bowel movement; CL, confidence limits; s.d., standard deviation; SSA, somatostatin analog; tid, 3 times per day.

−0.12). There was no statistically significant difference
between the telotristat ethyl 250 mg group and the placebo
group (P = 0.09), with the Hodges–Lehmann estimator at
−0.20 (95% CL −0.45, 0.02).
During the DBT period, there were no statistically
significant changes in cutaneous flushing, abdominal
pain or frequency of rescue SSA therapy to treat CS
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symptoms. There was also no trend in the change from
baseline in the number of rescue short-acting SSAs used
to treat bowel-related CS symptoms across all time points
in the DBT period, with mean changes of −0.01 counts
per day (s.d. 0.14), −0.07 (s.d. 0.35) and 0.01 (s.d. 0.10)
for placebo, telotristat ethyl 250 mg and telotristat ethyl
500 mg, respectively.
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Mean Changes From Baseline in BMs
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DBT period

OLE period

Discussion
There is a substantial need for safe and effective treatment
to supplement the current standard of care of SSA therapy
for the management of CS including diarrhea. Toward
this end, this study met both primary safety and efficacy
endpoints in the 12-week DBT period comparing 2 dosing
regimens of telotristat ethyl vs placebo. During both the
12-week DBT period and the OLE period of up to 36 weeks,
treatment with telotristat ethyl was well tolerated, as
indicated by the rarity of SAEs or discontinuations due
to AEs. Overall, TEAEs and discontinuations due to TEAEs
were similar among all treatment groups.
Notably, patients in this study had considerable
comorbidities associated with metastatic NETs, such as
gastrointestinal symptoms (most commonly diarrhea),
metabolic and nutrition disorders and cardiac disorders,
and patients were an average of 7.8 years since their
diagnosis of a NET at inclusion in this study. Despite
these comorbidities and the length of follow-up, there
were no deaths during the DBT or OLE period, and more
SAEs occurred in the placebo group compared with the
telotristat ethyl groups during the DBT period.
The results for depression-related AEs were favorable
compared with those reported in the phase 3 TELESTAR
study. Previously, there has been a concern about
depression with telotristat ethyl because of the known
role of serotonin in depression; the pharmacologic
profiles of earlier tryptophan hydroxylase inhibitors,
which crossed the blood–brain barrier; and the reported
numerically higher incidence of depression on telotristat
ethyl 500 mg tid than on telotristat ethyl 250 mg tid or
placebo during the TELESTAR study (Kulke et al. 2017).
As reported here in the TELECAST study, during the DBT
period, depression-related AEs were reported more often
on placebo (2 patients) compared with either dosage
http://erc.endocrinology-journals.org
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Figure 3
Mean changes from baseline (B) in frequency of
bowel movements per day. The change in mean
daily bowel movement (BM) frequency was
assessed weekly over the double-blind treatment
(DBT) and open-label extension (OLE) periods of
the study. The dotted lines indicate the crossover
of patients from either placebo or telotristat
ethyl 250 mg 3 times per day (tid) to telotristat
ethyl 500 mg tid in the OLE period.

of telotristat ethyl (1 patient in each treatment group)
during the DBT period. During the OLE period, depression
led to discontinuation of therapy in 2 patients. Overall, in
TELECAST, there was no imbalance in depression-related
AEs during the DBT period. The slightly higher incidence
of depression observed with telotristat ethyl 500 mg tid in
the OLE period (11.9%) compared with the same dosage
during the DBT period (4%) suggests that the emergence of
depression could be time dependent. However, telotristat
ethyl is unlikely to cross the blood–brain barrier (Liu et al.
2008, Lapuerta et al. 2015), and the depression observed
in TELESTAR and TELECAST might be related to the
underlying disease or other causes; nevertheless, patients
should be monitored for the occurrence of depression or
depressed mood.
Consistent with the results of the TELESTAR study,
elevations in hepatic enzymes appeared to be associated
with telotristat ethyl (Kulke et al. 2017). Elevated hepatic
enzymes (primarily GGT, with some elevations in ALT, AST
and ALP) were observed in some patients, but there were
no reported cases with clinically significant outcomes and
no cases of coincident substantial increases in bilirubin.
Constipation also appeared to be drug related,
and this is consistent with the mechanism of action of
telotristat ethyl. In this study, most constipation-related
AEs were mild to moderate in severity and resulted in no
discontinuations of the study drug. However, symptoms
of severe constipation or severe, persistent or worsening
abdominal pain should be watched for, and if observed,
telotristat ethyl should be discontinued to minimize the
risk of possible complications.
A significant (P < 0.001) reduction in u5-HIAA levels
was observed compared with baseline in patients given
telotristat ethyl vs placebo during the 12-week DBT
period. This reduction persisted during the OLE period.
Elevated levels of u5-HIAA in patients with CS have been
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associated with valvular heart disease, mesenteric fibrosis
and poor long-term survival (van der Horst-Schrivers et al.
2007, Druce et al. 2009, Davar et al. 2017). Telotristat
ethyl also significantly reduced BM frequency compared
with placebo and produced a durable reduction in BM
frequency in 40% of patients, similar to the results of
the TELESTAR study (Kulke et al. 2017). BM frequency
for patients not on SSA therapy also improved; however,
the small number of patients not on SSAs and the lack of
patients in this category who were randomly assigned to
receive placebo limit definitive conclusions. The weight
increase observed in some patients in the telotristat ethyl
groups could be the result of diarrhea control leading to
better nutritional status.
The effects of telotristat ethyl on u5-HIAA and the
BM symptoms associated with production of serotonin
by NETs are consistent with results from previous
studies and with telotristat ethyl’s selective inhibition of
intratumoral serotonin production (Kulke et al. 2017).
Whereas the phase 3 TELESTAR study demonstrated the
effect of telotristat ethyl in patients with CS diarrhea with
≥4 BMs/day, this study showed a statistically significant
effect on u5-HIAA levels and BMs/day in patients with less
frequent BMs and elevated u5-HIAA.
In conclusion, treatment with telotristat ethyl for
up to 48 weeks had a favorable safety profile, was well
tolerated and was associated with sustained reductions
in u5-HIAA and BM frequency. Data from this study and
from the previous phase 3 TELESTAR study support the
use of telotristat ethyl as an addition to SSAs in patients
with CS diarrhea.

Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
ERC-17-0455.
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